“Functional ¹²⁹Xe MRI Response to Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis”

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of Interest: Gregory P Barton reports support for the present manuscript from NIAID T32AI007635.

Conflict of Interest: Luis Torres reports support for the present manuscript from Flywheel.

Conflict of Interest: Jeff Kammerman grants or contracts from Polarean PLC., outside the submitted work; Patents planned, issued or pending Wisconsin Alumni Research Foundation, Co-inventor on patent related to Xenon MRI held by WARF.

Conflict of Interest: Katherine J. Carey reports grants or contracts from Imbio Inc.; consulting fees from Imbio Inc.; stock options for Imbio Inc.; employee of Imbio Inc., all disclosures made outside the submitted work.

Conflict of Interest: Mark L. Schiebler reports support for the present manuscript from NIH/HLBI; grants or contracts from DHHS, PHS, NIH, and NIH/NHLBI, outside the submitted work; Deputy Editor Radiology; Other financial or non-financial interests Shareholder: X-Vax,Inc., Elucent Medical, Inc., Elucida Oncology, Inc.

Conflict of Interest: Sean B. Fain reports support for the present manuscript from NIH/NHLBI, American Lung Association, and GE Healthcare; grants or contracts from Polarean PLC., outside the submitted work; consulting fees from Sanofi/Regeneron, and Polarean PLC., outside the submitted work; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi/Regeneron, and Polarean PLC.